Viagra Shows Promise in Treating Rare Leigh Syndrome, Study Finds

MONTREAL — Sildenafil, commonly known by the brand name Viagra, is showing unexpected promise as a potential treatment for Leigh syndrome, a rare and devastating genetic disorder that typically manifests in early childhood. Preliminary research suggests the drug may alleviate some symptoms and, in some cases, modestly extend life expectancy in animal models and a small number of patients. While these findings are encouraging, experts emphasize that much more research is needed to confirm these effects and determine the optimal use of sildenafil for this condition.

Understanding Leigh Syndrome: A Rare Metabolic Challenge

Leigh syndrome is a severe neurological disorder that arises from defects in mitochondrial function. Mitochondria are often called the “powerhouses of the cell,” responsible for generating the energy needed for organ and body systems to function. When mitochondria don’t work properly, it can lead to a range of debilitating symptoms, particularly affecting the brain and muscles. The disease typically appears before a child’s second birthday and often leads to death within a few years, though symptom onset can sometimes occur later in life. Symptoms can include difficulty breathing and swallowing, muscle weakness and progressive loss of motor skills. There are multiple genetic causes for Leigh syndrome, making diagnosis and treatment particularly complex. As Dr. Grant Mitchell, a geneticist at CHU Sainte-Justine, points out, “There are multiple forms of Leigh syndrome and We see not certain that all forms would respond in the same way to sildenafil treatment.”

How Sildenafil Entered the Picture: From Blood Vessels to Mitochondria

The potential link between sildenafil and Leigh syndrome emerged from laboratory research focused on restoring proper electrical charge within mitochondria. Researchers discovered that a specific gene, MT-ATP6, appears to be linked to an abnormal electrical charge in the mitochondrial membrane. Screening nearly 6,000 molecules, they found that sildenafil was particularly effective in normalizing this charge. Further in vitro (in test tubes) and in vivo (in living organisms) studies confirmed the drug’s potential to correct some of the underlying problems associated with the disease. This research builds on the known effects of sildenafil as a vasodilator – a drug that widens blood vessels – but the precise mechanism by which it impacts mitochondrial function remains unclear. As Dr. Mitchell notes, “The way the medication has produced the effects remains speculative… It’s not clear by what pathway the taking of sildenafil is linked to the effects (beneficial).”

Early Clinical Observations: A Glimmer of Hope, But Caution Remains

Following the promising pre-clinical results, researchers initiated a small pilot study involving six patients with Leigh syndrome. One 16-year-old patient, who was rapidly deteriorating and facing palliative care, experienced symptom improvement over seven years while on sildenafil, though he still requires assistance with walking. Four other patients showed modest improvements, while one had to discontinue treatment due to side effects. These initial findings, published in the journal Cell, are encouraging, but researchers are quick to emphasize the limitations of the study. The sample size is small, the study focused on a single form of the disease, and the follow-up period was relatively short. It’s also important to consider that Leigh syndrome can have an episodic course, with symptoms fluctuating naturally, making it challenging to isolate the drug’s specific effect. CityNews Montreal reported on these findings on March 21, 2026.

The Quebec Connection: A Unique Genetic Factor

Interestingly, a specific form of Leigh syndrome is more prevalent in Quebec than elsewhere, due to a historical genetic founder effect. This means a particular gene variant became more common in the population due to the limited gene pool of early settlers. However, this specific form of the disease was not the focus of the recent study, adding another layer of complexity to understanding sildenafil’s potential impact across all subtypes of Leigh syndrome.

What Does This Signify for Patients and Families?

The emerging research on sildenafil and Leigh syndrome offers a potential new avenue for treatment, a condition currently considered incurable. However, it’s crucial to understand that this is still very early-stage research. Sildenafil is not a cure, and its effectiveness may vary depending on the specific genetic cause of the disease. Families affected by Leigh syndrome should not seek out sildenafil treatment outside of a clinical trial setting. Any decisions regarding treatment should be made in consultation with a qualified medical professional specializing in mitochondrial disorders. Science.org highlights that while animal studies and preliminary human data support the safety of sildenafil in Leigh syndrome, its effectiveness remains unproven.

Next Steps: Rigorous Research and Clinical Trials

Researchers are now focused on conducting larger, more rigorous clinical trials to evaluate the efficacy and safety of sildenafil in a broader range of patients with Leigh syndrome. These trials will need to carefully control for factors such as disease subtype, age of onset, and disease severity. Further research is also needed to elucidate the precise mechanisms by which sildenafil may be exerting its beneficial effects. The scientific community is also exploring whether sildenafil could be combined with other therapies to achieve even greater improvements in patient outcomes. SciTechDaily reports that researchers used brain organoids – three-dimensional replicas of the brain grown from patient stem cells – to test the effects of sildenafil in the laboratory.

Ongoing Surveillance and Guidance Updates: The medical community will continue to monitor emerging research on sildenafil and Leigh syndrome. Official treatment guidelines will be updated as new evidence becomes available. Patients and families are encouraged to stay informed through reputable sources such as the United Mitochondrial Disease Foundation (https://www.umdf.org/) and their healthcare providers.